Business
Calquence fixed-duration combo improved 1L CLL PFS
Calquence fixed-duration combo improved 1L CLL PFS.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n29 July 2024\n \nFixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial\n \nFavourable trend in overall survival was also observed\n \nPositive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL).\n \nFor the secondary endpoint of overall survival (OS), a trend was observed in favour of Calquence in combination with venetoclax, with or without obinutuzumab, versus standard-of-care chemoimmunotherapy. The OS data were not mature at the time of this analysis and the trial will continue to assess OS as a key secondary endpoint.\n \nCLL is caused by the abnormal production of white blood cells and is the most prevalent type of leukaemia in adults worldwide, with numbers anticipated to grow.1-3 In the first-line setting, approximately 40,000 patients are treated with the current standard of care.4 Although CLL is considered an incurable cancer, patients often live with the disease for many years, and may remain on continuous treatment.5\n \nJennifer R. Brown, MD, PhD, Director of the CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and the Worthington and Margaret Collette Professor of Medicine at Harvard Medical School, and principal investigator of the trial, said: \"The AMPLIFY results demonstrate the potential of acalabrutinib and venetoclax with or without obinutuzumab to be effective and well-tolerated fixed-duration treatment options for patients with chronic lymphocytic leukaemia. This is an important advance in this setting as fixed-duration regimens allow those living with this chronic disease to take breaks from their treatment, thereby decreasing the possibility of long-term adverse events and drug resistance and improving quality of life.\"\n \nSusan Galbraith, Executive Vice President, Oncology R&D,...